ARTICLE | Clinical News

Topotarget preclinical data

December 7, 2009 8:00 AM UTC

In a mouse model of androgen receptor (AR)-expressing prostate cancer, 20 mg/kg intraperitoneal belinostat significantly suppressed tumor growth vs. control, and 40 mg/kg belinostat reduced mean final tumor volume by 60% vs. control. In a mouse model of AR-negative prostate cancer, belinostat reduced tumor proliferation by about 47% vs. control. ...